Table 2.
Clinical trials of adipose-derived stem cells and mesenchymal stem cells inflammatory bowel disease therapies
Ref. | Disease | Phase | No. of patients | Stem cell source | Route | Outcome |
de la Portilla et al[15] | Complex perianal fistula | I/II | 24 | ASC; Allo-adipose | Intralesional | Improved |
Lee et al[20] | Crohn’s fistula | II | 43 | ASC; Allo-adipose | Intralesional | Improved |
Cho et al[13] | Crohn’s fistula | I | 10 | ASC; Allo-adipose | Intrafistula | Improved |
Herreros et al[19] | Complex cryptoglandular perianal fistula | III | 200 | ASC; Allo-adipose | Intrafistula | Improved |
Guadalajara et al[18] | Complex perianal fistula | II | 24 | ASC; Allo-liposuction | Intrafistula | Improved |
Ciccocioppo et al[14] | Crohn’s fistula | I/II | 12 | MSC; Allo-BM | Intrafistula | Improved |
Garcia-Olmo et al[17] | Complex perianal fistula | II | 14 | ASC; Auto-adipose | Intrafistula | Improved |
García-Olmo et al[16] | Crohn’s fistula | I | 10 | ASC; Allo-adipose | Intrafistula | Improved |
ASC: Adipose-derived stem cells; MSC: Mesenchymal stem cells.